| Name | Title | Contact Details |
|---|
ADEC Innovations seamlessly delivers fully integrated, cost-effective industry expertise, business process & data management, and software services. Our mission: to ensure we meet your ever-evolving ESG needs and help you improve sustainability performance, gain unprecedented insights, optimize resource use, and drive operational efficiencies. With a global force of over 3,500 employees, our presence spans five continents – Asia, Australia, Europe, Africa and North America. We offer a wide range of solutions and consulting services across multiple fields, providing industry expertise in sustainability, environmental data services, knowledge management, data management, health information, and public-private partnerships. In all these business areas, we focus on aggregating, organizing and giving visibility to data in order to enable client organizations leaders and stakeholders to make informed decisions. Our comprehensive suite of ESG Solutions assist organizations in minimizing negative social and environmental impacts, maximize efficiency, and drive long-term business growth through sustainable profitability and empowered decision making.
SMSI is a small business providing management and technical/engineering services to the DOE/NNSA, national laboratories, and industrial clients. Our work with nuclear facility operations and safety has set the standard for excellence. We are the resource for highly technical engineering and nuclear safety basis development, review, and implementation at the national laboratories. SMSI has a demonstrated record of success providing superior people developing and implementing innovative solutions, delivering projects on time and within budget. We build productive relationships by being highly responsive to our customers. Operations began in 2000 with headquarters in Albuquerque, NM, and currently operating offices in Los Alamos, NM and Oak Ridge, TN.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.